Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution

Published: Wednesday, May 26, 2010
Last Updated: Wednesday, May 26, 2010
Bookmark and Share
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.

Exiqon A/S and MultiD Analyzes AB have announced a Development and Distribution Agreement incorporating a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform. The agreement allows Exiqon to sell a fully compatible and comprehensive data analysis solution to complete their microRNA qPCR offering.

“The partnership between MultiD and Exiqon has lead to the development of a customized version of the advanced GenEx data analysis program which has been specifically adapted to allow easy pre-processing and analysis of data from the Exiqon microRNA PCR panels and assays,” said Henrik M. Pfundheller, VP Sales & Marketing of Exiqon.

Pfundheller continued, “Exiqon offers the best performing qPCR reagents for microRNA expression profiling on the market. However, we feel it is just as important that our customers process, normalize and analyze their qPCR data properly and with confidence. The addition of the Exiqon GenEx software to our microRNA qPCR portfolio enables customers to get the most out of their microRNA expression profiling experiments in an easy and convenient way”.

MultiD's GenEx software is well established software for processing and analysis of qPCR data. It includes everything from selection and validation of reference genes, data pre-processing and advanced statistical methods to analyze real-time qPCR data with simple clicks of the mouse. Possibly the most important part of qPCR experiments is the pre-processing of raw data for subsequent statistical analysis. Pre-processing steps need to be performed with consistence, in the correct order and with confidence.

Exiqon's miRCURY LNA™ Universal RT microRNA PCR system offers the best available combination of performance and ease-of-use on the microRNA real-time PCR market. The use of two LNA™-enhanced PCR primers results in both sensitivity and specificity, enabling quantification of very low microRNA levels and discrimination between closely related microRNA sequences.

The universal RT step reduces sample input requirements and technical variation, and saves time in the laboratory. The product line includes microRNA Ready-to-Use PCR panels for sensitive expression profiling of 730 human microRNAs, individual microRNA assays, reference gens and reagent kits.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.
Wednesday, June 23, 2010
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!